Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2012 Jun 6;3(3):309-17.
doi: 10.1111/j.2040-1124.2011.00185.x.

Efficacy and safety of ginsam, a vinegar extract from Panax ginseng, in type 2 diabetic patients: Results of a double-blind, placebo-controlled study

Affiliations

Efficacy and safety of ginsam, a vinegar extract from Panax ginseng, in type 2 diabetic patients: Results of a double-blind, placebo-controlled study

Ji Won Yoon et al. J Diabetes Investig. .

Abstract

Aims/Introduction: The efficacy, dose-response relationship and safety of ginsam, a vinegar extract from Panax ginseng, were evaluated in an 8-week, double-blind, randomized, placebo-controlled study in drug-naïve patients with type 2 diabetes.

Materials and methods: A total of 72 diabetic patients were randomized to receive 1500, 2000 or 3000 mg of ginsam, or placebo daily for 8 weeks (n = 18 in each group). The primary end-point was the changes from the baseline HbA1c level. The secondary end-points were the changes of fasting and postprandial 2-h glucose concentration, and the proportion of patients achieving a reduction in HbA1c >0.5%.

Results: In the intention-to-treat analysis, ginsam treatment reduced HbA1c level significantly: -0.56 ± 0.25% in the 1500 mg group, -0.31 ± 0.12% in the 2000 mg group, and -0.29 ± 0.11% in the 3000 mg group (all P < 0.05), with a significant difference between the 1500 mg ginsam and the placebo group (-0.02 ± 0.12%, P = 0.021). The changes in fasting glucose concentration followed the same pattern: -21.40, -14.27 and -6.76 mg/dL for 1500, 2000, and 3000 mg, respectively, vs -2.25 mg/dL for the placebo. The percentage of patients whose HbA1c level decreased by >0.5% differed significantly between the placebo group (11.1%) and the 1500 mg (27.8%) and 2000 mg (27.8%) groups. No severe adverse events were observed in any group.

Conclusions: An 8-week treatment with ginsam, a vinegar extract from P. ginseng, moderately improved HbA1c level and was well tolerated in type 2 diabetic patients with inadequate glycemic control. This trial was registered with ClinicalTrial.Gov (no. NCT01008163). (J Diabetes Invest, doi: 10.1111/j.2040-1124.2011.00185.x, 2011).

Keywords: Ginsam; Oral antidiabetic therapy; Panax ginseng.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Flow chart of enrolment of the study subjects.
Figure 2
Figure 2
Changes of HbA1c level, and fasting and postload glucose concentration and percentage of patients whose HbA1c decreased by >0.5% during 8 weeks of treatment with ginsam.
Figure 3
Figure 3
Correlations between the changes of HbA1c and the changes of tumor necrosis factor‐α (TNF‐α) or interleukin‐6 (IL‐6) levels. The changes of HbA1c were positively and significantly correlated with changes of TNF‐α and IL‐6.

References

    1. Bahrke MS, Morgan WR. Evaluation of the ergogenic properties of ginseng: an update. Sports Med 2000; 29: 113–133 - PubMed
    1. Dubick MA. Historical perspectives on the use of herbal preparations to promote health. J Nutr 1986; 116: 1348–1354 - PubMed
    1. Vogler BK, Pittler MH, Ernst E. The efficacy of ginseng. A systematic review of randomised clinical trials. Eur J Clin Pharmacol 1999; 55: 567–575 - PubMed
    1. Leung KW, Wong AS. Pharmacology of ginsenosides: a literature review. Chin Med 2010; 5: 1–7 - PMC - PubMed
    1. Lu JM, Yao Q, Chen C. Ginseng compounds: an update on their molecular mechanisms and medical applications. Curr Vasc Pharmacol 2009; 7: 293–302 - PMC - PubMed

LinkOut - more resources